have shown that intracoronary administration of autologous CD34+ cell therapy effectively alleviates angina and endothelial dysfunction in non-obstructive coronary artery disease, highlighting the potential of this therapeutic approach to address these complex cardiovascular conditions. The gene discussed is CD34; the disease is angina pectoris.